Latest From Graham Scholefield
Global Biopharma R&D Productivity And Growth Rankings
Catenion, a biopharma-focused R&D strategy consulting firm, has analyzed the performance of the top-30 biopharma companies in 2018 and outlined major concerns for the future of innovation in drug development.
Methodology: R&D Productivity Ranking
To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion takes an approach that focuses on value.
Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap
Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.
Biopharma R&D Productivity And Growth 2016: Innovation Performance Improves
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.
Methodology: R&D Productivity Ranking
To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion's methodology takes an approach that focuses on value.
Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.